Skip to content

Pear Therapeutics, Inc.

CIK 0001835567

← back to feed
Revenue (TTM)
$11.44M
+201.7% YoY FY Mar 2023
Net Income (TTM)
−$80.42M
−15.9% YoY FY Mar 2023
EPS Diluted (TTM)
−$0.63
+5.3% YoY FY Mar 2023
Gross Margin
25.2%
FY Mar 2023
Operating Margin
-1,071.2%
FY Mar 2023
Net Margin
-703.0%
FY Mar 2023
Free Cash Flow (TTM)
−$117.37M
FY Mar 2023
Cash
$48.3M
FY Mar 2023
Total Debt
$27.45M
FY Mar 2023
Shares Outstanding
142.74M sh
FY Mar 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings